Disc Medicine, Inc.
IRONHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients. The company carries a $2.70B market cap, placing it firmly in the mid-cap category. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Market Cap
$2.70B
Beta
2.14
P/E (TTM)
—
P/E (Fwd)
-9.43
EPS (TTM)
$-6.74
EPS (Fwd)
$-7.50
ROE
-35.8%
ROA
-22.7%
Cash
$730.2M
Total Debt
$31.1M
Free CF
-$121.4M
52W Change
51.7%
Annual Financials
Cash vs Debt
Disc Medicine, Inc. holds $730.2M in cash against $31.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$121.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -35.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, IRON tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, IRON has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IRON.